NEOPLASTIC AND NORMAL T CELL DIFFERENTIATION ANTIGENS
NEOPLASTIC AND NORMAL T CELL DIFFERENTIATION ANTIGENS
批准号:
3181921
负责人:
JOHN G. FRELINGER
金额:
$11.32万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1986
资助国家:
美国
项目状态:
已结题
起止时间:
1986-01-01 至 1989-06-30
中文摘要
这项研究的目的是获得基本的结构、遗传和
一种新的小鼠T细胞分化抗原的生物学信息
(BM100)。用单抗筛查正常和非霍奇金淋巴瘤的初步结果
肿瘤细胞提示BM100是T细胞特异性的,除非它是
在很高比例的骨髓细胞上发现。基于这一发现,
似乎BM100存在于前T细胞上。这一假设将是
通过包括流式细胞术在内的多种技术进行检查,
免疫印迹和骨髓嵌合体。关于的结构信息
蛋白质将使用免疫印迹、凝集素柱、放射性标记、
以及一维和二维凝胶分析。编码BM100的cDNA
将使用cDNA表达载体从T细胞肿瘤中分离抗原
Lambda gt11。这些克隆将被测序并用于遗传图谱
学习。它们还将被用于分离和鉴定基因组
克隆人。BM100很有趣,因为它可能代表着最早的
T细胞的标记物。BM100也很有趣,因为它可能
代表人类抗原(GpL115)的小鼠同源物。GpL115
最近发现,慢性阻塞性肺疾病患者的分子水平发生了变化
Wiskott-Aldrich综合征,一种X连锁的免疫缺陷疾病,它
在其他缺陷中,T细胞异常,经常导致
淋巴网状恶性肿瘤。
英文摘要
The purpose of this research is to obtain basic structural, genetic, and
biological information on a novel mouse T cell differentiation antigen
(BM100). Initial findings using a monoclonal antibody to screen normal and
neoplastic cells suggest that BM100 is T cell specific except that it is
found on a high pecentage of bone marrow cels. Based on this finding it
appears that BM100 is present on pre-T cells. This hypothesis will be
examined by a combination of techniques including flow cytometry,
immunoblots, and bone-marrow chimeras. Structural information on the
protein will be obtained using immunoblots, lectin columns, radiolabelling,
and one and two dimensional gel analysis. The cDNAs encoding the BM100
antigen will be isolated from a T cell tumor using a cDNA exprssion vector
lambda gt11. These clones will be sequenced and used in genetic mapping
studies. They will also be used to isolate and characterize genomic
clones. The BM100 is interesting since it may represent the earliest
marker of T lineage cells. The BM100 is also interesting since it may
represent the mouse homolog of a human antigen (gpL115). The gpL115
molecule has recently been found to be altered in patients with
Wiskott-Aldrich Syndrome, an X-linked immunodeficiency disorder, which
among other defects has T cell abnormalities and often leads to
lymphoreticular malignancies.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
CD43 (leukosialin, sialophorin, large sialoglycoprotein) can be expressed in both normal and Wiskott-Aldrich fibroblasts via transfection of a leukosialin cDNA.
通过转染白唾液酸蛋白 cDNA,CD43(白唾液酸蛋白、唾液酸蛋白、大唾液酸糖蛋白)可在正常成纤维细胞和 Wiskott-Aldrich 成纤维细胞中表达。
DOI:
10.1002/eji.1830200703
发表时间:
1990
期刊:
European journal of immunology
影响因子:
5.4
作者:
[Pallant,A, Fukuda,M, Frelinger,JG]
通讯作者:
Frelinger,JG
Reduced tumorigenicity of a spontaneous mouse lung carcinoma following H-2 gene transfection.
H-2 基因转染后自发性小鼠肺癌的致瘤性降低。
DOI:
10.1073/pnas.84.13.4562
发表时间:
1987
期刊:
Proceedings of the National Academy of Sciences of the United States of America
影响因子:
11.1
作者:
[Bahler,DW, Frelinger,JG, Harwell,LW, Lord,EM]
通讯作者:
Lord,EM
Molecular analysis of deficient class I H-2 antigen expression by mouse lung carcinoma cells.
小鼠肺癌细胞 I 类 H-2 抗原表达缺陷的分子分析。
DOI:
--
发表时间:
1988
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Bahler,DW, Cerosaletti,KM, Lord,EM, Frelinger,JG]
通讯作者:
Frelinger,JG
Developing novel strategies for altering the cytokine microenvironment of tumors
-
批准号:8957973
-
项目类别:
-
资助金额:$16.69万
-
财政年份:2015
-
负责人:JOHN G. FRELINGER
-
依托单位:
Developing novel strategies for altering the cytokine microenvironment of tumors
-
批准号:9105713
-
项目类别:
-
资助金额:$20.03万
-
财政年份:2015
-
负责人:JOHN G. FRELINGER
-
依托单位:
TARGETED CTL MEDIATED IMMUNITY FOR PROSTATE CANCER
-
批准号:2517707
-
项目类别:
-
资助金额:$18.64万
-
财政年份:1996
-
负责人:JOHN G. FRELINGER
-
依托单位:
TARGETED CTL MEDIATED IMMUNITY FOR PROSTATE CANCER
-
批准号:2902203
-
项目类别:
-
资助金额:$23.5万
-
财政年份:1996
-
负责人:JOHN G. FRELINGER
-
依托单位:
TARGETED CTL MEDIATED IMMUNITY FOR PROSTATE CANCER
-
批准号:2114154
-
项目类别:
-
资助金额:$17.74万
-
财政年份:1996
-
负责人:JOHN G. FRELINGER
-
依托单位:
TARGETED CTL MEDIATED IMMUNITY FOR PROSTATE CANCER
-
批准号:6172970
-
项目类别:
-
资助金额:$24.52万
-
财政年份:1996
-
负责人:JOHN G. FRELINGER
-
依托单位:
TARGETED CTL MEDIATED IMMUNITY FOR PROSTATE CANCER
-
批准号:6376240
-
项目类别:
-
资助金额:$25.25万
-
财政年份:1996
-
负责人:JOHN G. FRELINGER
-
依托单位:
TARGETED CTL MEDIATED IMMUNITY FOR PROSTATE CANCER
-
批准号:2769849
-
项目类别:
-
资助金额:$19.37万
-
财政年份:1996
-
负责人:JOHN G. FRELINGER
-
依托单位:
NEOPLASTIC AND NORMAL T CELL DIFFERENTIATION ANTIGENS
-
批准号:3181917
-
项目类别:
-
资助金额:$12.3万
-
财政年份:1986
-
负责人:JOHN G. FRELINGER
-
依托单位:
NEOPLASTIC AND NORMAL T CELL DIFFERENTIATION ANTIGENS
-
批准号:3181920
-
项目类别:
-
资助金额:$10.98万
-
财政年份:1986
-
负责人:JOHN G. FRELINGER
-
依托单位:
海外基金